{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:52:46Z","timestamp":1785815566304,"version":"3.56.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The glucocorticoid receptor (GR) is a nuclear receptor protein for cortisol and other glucocorticoids and regulates the transcription of thousands of genes involved in metabolism, development, stress and inflammatory response. In prostate cancer, GR may confer resistance to anti-androgen receptor therapies by bypassing AR blockade. However, only few data are available on the prognostic role of GR expression in prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To estimate the prognostic value of GR, a tissue microarray containing 17,747 prostate cancers with associated follow-up and molecular data was analyzed by immunohistochemistry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All patients had undergone radical prostatectomy. GR immunostaining was found in 10,832 (89.1%) of 12,125 interpretable tumors, including 48.5% with weak, 29.8% with moderate and 11% with strong staining intensity. Increased GR staining was strongly linked to adverse feature of the disease, including high tumor stage (pT), high classical and quantitative Gleason grade, presence of nodal metastases (pN+), a positive surgical margin (R1) status, and early biochemical recurrence (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001 each). A multivariate analysis showed that the prognostic value of strong GR staining was independent of pT, Gleason grade, pN and R status. High level GR staining was significantly linked to TMPRSS2:ERG fusion (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and high androgen receptor expression (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001 each). A combined analysis of the impact of GR and AR on patient prognosis identified the best prognosis for AR\n                      <jats:sup>neg<\/jats:sup>\n                      \/GR\n                      <jats:sup>neg<\/jats:sup>\n                      cancers while AR\n                      <jats:sup>pos<\/jats:sup>\n                      \/GR\n                      <jats:sup>pos<\/jats:sup>\n                      cancers showed the worst prognosis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Moreover, high GR expression was a strong predictor of poor prognosis in AR low, AR intermediate and AR high cancers (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001 each).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High level expression of GR is strongly linked to prostate cancer aggressiveness in uni- and multivariate analysis. GR immunohistochemistry \u2013 alone or in combination with other markers \u2013 holds great potential to identify patients with a high risk for tumor progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-025-01046-8","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:37:46Z","timestamp":1762310266000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["High level expression of glucocorticoid receptor (GR) is linked to aggressive tumor features, early biochemical recurrence, and genetic instability in prostate cancer"],"prefix":"10.1038","volume":"29","author":[{"given":"Neele","family":"Heckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Plage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0158-4258","authenticated-orcid":false,"given":"Ronald","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1572-8200","authenticated-orcid":false,"given":"Maximilian","family":"Lennartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Fraune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Krech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lebok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Minner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Burandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till S.","family":"Clauditz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Wilczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Gorbokon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3841-444X","authenticated-orcid":false,"given":"Morton","family":"Freytag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Reiswich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Viehweger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Chirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Heinzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9339-9521","authenticated-orcid":false,"given":"Alexander","family":"Haese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Schlomm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Steurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bernreuther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Ralla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7884-4313","authenticated-orcid":false,"given":"David","family":"Dum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hinsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M.","family":"Luebke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Menz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Schlichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Erber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Biernath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"1046_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1210\/er.2014-1010","volume":"35","author":"S Vandevyver","year":"2014","unstructured":"Vandevyver S, Dejager L, Libert C. Comprehensive overview of the structure and regulation of the glucocorticoid receptor. Endocr Rev. 2014;35:671\u201393. https:\/\/doi.org\/10.1210\/er.2014-1010.","journal-title":"Endocr Rev"},{"key":"1046_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17:233\u201347. https:\/\/doi.org\/10.1038\/nri.2017.1.","journal-title":"Nat Rev Immunol"},{"key":"1046_CR3","doi-asserted-by":"publisher","unstructured":"Noureddine LM, Tredan O, Hussein N, Badran B, Le Romancer M, Poulard C. Glucocorticoid receptor: a multifaceted actor in breast cancer. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22094446.","DOI":"10.3390\/ijms22094446"},{"key":"1046_CR4","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1530\/ERC-20-0489","volume":"28","author":"I Mayayo-Peralta","year":"2021","unstructured":"Mayayo-Peralta I, Zwart W, Prekovic S. Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene? Endocr Relat Cancer. 2021;28:R157\u2013R71. https:\/\/doi.org\/10.1530\/ERC-20-0489.","journal-title":"Endocr Relat Cancer"},{"key":"1046_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-1-4939-2895-8_14","volume":"872","author":"MA Pufall","year":"2015","unstructured":"Pufall MA. Glucocorticoids and cancer. Adv Exp Med Biol. 2015;872:315\u201333. https:\/\/doi.org\/10.1007\/978-1-4939-2895-8_14.","journal-title":"Adv Exp Med Biol"},{"key":"1046_CR6","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-06-0749","volume":"12","author":"A Yano","year":"2006","unstructured":"Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res. 2006;12:6012\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0749.","journal-title":"Clin Cancer Res"},{"key":"1046_CR7","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/sj.onc.1209991","volume":"26","author":"A Yemelyanov","year":"2007","unstructured":"Yemelyanov A, Czwornog J, Chebotaev D, Karseladze A, Kulevitch E, Yang X, et al. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene. 2007;26:1885\u201396. https:\/\/doi.org\/10.1038\/sj.onc.1209991.","journal-title":"Oncogene"},{"key":"1046_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12672-014-0173-2","volume":"5","author":"M Isikbay","year":"2014","unstructured":"Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014;5:72\u201389. https:\/\/doi.org\/10.1007\/s12672-014-0173-2.","journal-title":"Horm Cancer"},{"key":"1046_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1163-y","volume":"35","author":"K Cheng","year":"2018","unstructured":"Cheng K, Liu X, Chen L, Lv JM, Qu FJ, Pan XW, et al. alpha-Viniferin activates autophagic apoptosis and cell death by reducing glucocorticoid receptor expression in castration-resistant prostate cancer cells. Med Oncol. 2018;35:105. https:\/\/doi.org\/10.1007\/s12032-018-1163-y.","journal-title":"Med Oncol"},{"key":"1046_CR10","doi-asserted-by":"publisher","unstructured":"Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, et al. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 2017;6. https:\/\/doi.org\/10.7554\/eLife.27861.","DOI":"10.7554\/eLife.27861"},{"key":"1046_CR11","doi-asserted-by":"publisher","unstructured":"Abida W, Hahn AW, Shore N, Agarwal N, Sieber P, Smith MR, et al. Phase 1 Study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer progressing on enzalutamide. Clin Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3508.","DOI":"10.1158\/1078-0432.CCR-23-3508"},{"key":"1046_CR12","doi-asserted-by":"publisher","first-page":"86339","DOI":"10.18632\/oncotarget.13404","volume":"7","author":"M Kluth","year":"2016","unstructured":"Kluth M, Graunke M, Moller-Koop C, Hube-Magg C, Minner S, Michl U, et al. Deletion of 18q is a strong and independent prognostic feature in prostate cancer. Oncotarget. 2016;7:86339\u201349. https:\/\/doi.org\/10.18632\/oncotarget.13404.","journal-title":"Oncotarget"},{"key":"1046_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2144\/04361RV01","volume":"36","author":"R Simon","year":"2004","unstructured":"Simon R, Mirlacher M, Sauter G. Tissue microarrays. Biotechniques. 2004;36:98\u2013105. https:\/\/doi.org\/10.2144\/04361RV01.","journal-title":"Biotechniques"},{"key":"1046_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/ijc.33344","volume":"148","author":"K Moller","year":"2021","unstructured":"Moller K, Kluth M, Ahmed M, Burkhardt L, Moller-Koop C, Buscheck F, et al. Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer. Int J Cancer. 2021;148:748\u201358. https:\/\/doi.org\/10.1002\/ijc.33344.","journal-title":"Int J Cancer"},{"key":"1046_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4161\/cc.11.2.18945","volume":"11","author":"A Yemelyanov","year":"2012","unstructured":"Yemelyanov A, Bhalla P, Yang X, Ugolkov A, Iwadate K, Karseladze A, et al. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality. Cell Cycle. 2012;11:395\u2013406. https:\/\/doi.org\/10.4161\/cc.11.2.18945.","journal-title":"Cell Cycle"},{"key":"1046_CR16","first-page":"211","volume":"28","author":"YS Guo","year":"2022","unstructured":"Guo YS, Wang WB, Zhang SD, Zhang MQ, Qi L, Gao JF, et al. Expression of glucocorticoid receptor in prostate cancer and its clinical significance. Zhonghua Nan Ke Xue. 2022;28:211\u20136.","journal-title":"Zhonghua Nan Ke Xue"},{"key":"1046_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/pros.21416","volume":"72","author":"RZ Szmulewitz","year":"2012","unstructured":"Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, et al. Serum\/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 2012;72:157\u201364. https:\/\/doi.org\/10.1002\/pros.21416.","journal-title":"Prostate"},{"key":"1046_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1158\/1078-0432.CCR-17-0989","volume":"24","author":"M Puhr","year":"2018","unstructured":"Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, et al. The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy. Clin Cancer Res. 2018;24:927\u201338. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0989.","journal-title":"Clin Cancer Res"},{"key":"1046_CR19","first-page":"889","volume":"2","author":"JL Mohler","year":"1996","unstructured":"Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA, Wilson EM, et al. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res. 1996;2:889\u201395.","journal-title":"Clin Cancer Res"},{"key":"1046_CR20","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/jnci\/93.22.1739","volume":"93","author":"K Nishimura","year":"2001","unstructured":"Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst. 2001;93:1739\u201346. https:\/\/doi.org\/10.1093\/jnci\/93.22.1739.","journal-title":"J Natl Cancer Inst"},{"key":"1046_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/CMAR.S124475","volume":"9","author":"TS Block","year":"2017","unstructured":"Block TS, Murphy TI, Munster PN, Nguyen DP, Lynch FJ. Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay. Cancer Manag Res. 2017;9:65\u201372. https:\/\/doi.org\/10.2147\/CMAR.S124475.","journal-title":"Cancer Manag Res"},{"key":"1046_CR22","doi-asserted-by":"publisher","unstructured":"Tsourlakis MC, Kind S, Dwertmann Rico S, Weidemann S, Moller K, Schlichter R, et al. Glucocorticoid Receptor (GR) expression in human tumors: a tissue microarray study on more than 14,000 tumors. Biomedicines. 2025;13. https:\/\/doi.org\/10.3390\/biomedicines13071683.","DOI":"10.3390\/biomedicines13071683"},{"key":"1046_CR23","doi-asserted-by":"publisher","first-page":"E27","DOI":"10.1002\/ijc.29147","volume":"136","author":"N Xie","year":"2015","unstructured":"Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, et al. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer. 2015;136:E27\u201338. https:\/\/doi.org\/10.1002\/ijc.29147.","journal-title":"Int J Cancer"},{"key":"1046_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00795-022-00332-x","volume":"55","author":"S Hata","year":"2022","unstructured":"Hata S, Shimada H, Sato N, Koshiishi M, Ise K, Ogata T, et al. Expression and clinicopathological significance of glucocorticoid receptor, SGK1, and NDRG1 in hormone-naive prostate carcinoma. Med Mol Morphol. 2022;55:283\u201391. https:\/\/doi.org\/10.1007\/s00795-022-00332-x.","journal-title":"Med Mol Morphol"},{"key":"1046_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ygyno.2017.04.012","volume":"146","author":"JT Veneris","year":"2017","unstructured":"Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, et al. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017;146:153\u201360. https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.012.","journal-title":"Gynecol Oncol"},{"key":"1046_CR26","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ygyno.2017.09.013","volume":"147","author":"IL Tangen","year":"2017","unstructured":"Tangen IL, Veneris JT, Halle MK, Werner HM, Trovik J, Akslen LA, et al. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecol Oncol. 2017;147:672\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2017.09.013.","journal-title":"Gynecol Oncol"},{"key":"1046_CR27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.gassur.2005.10.004","volume":"10","author":"DC Yeh","year":"2006","unstructured":"Yeh DC, Cheng SB, Yu CC, Ho WL, Wu CC, Liu TJ, et al. Role of glucocorticoid receptor in serosa-involved gastric carcinoma after gastrectomy. J Gastrointest Surg. 2006;10:706\u201311. https:\/\/doi.org\/10.1016\/j.gassur.2005.10.004.","journal-title":"J Gastrointest Surg"},{"key":"1046_CR28","doi-asserted-by":"publisher","first-page":"6360","DOI":"10.1158\/0008-5472.CAN-11-0362","volume":"71","author":"D Pan","year":"2011","unstructured":"Pan D, Kocherginsky M, Conzen SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011;71:6360\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0362.","journal-title":"Cancer Res"},{"key":"1046_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1067\/msy.2002.118710","volume":"131","author":"WL Ho","year":"2002","unstructured":"Ho WL, Wu CC, Yeh DC, Chen JT, Huang CC, Lin YL, et al. Roles of the glucocorticoid receptor in resectable hepatocellular carcinoma. Surgery. 2002;131:19\u201325. https:\/\/doi.org\/10.1067\/msy.2002.118710.","journal-title":"Surgery"},{"key":"1046_CR30","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1158\/1078-0432.CCR-19-1603","volume":"26","author":"Y Mitani","year":"2020","unstructured":"Mitani Y, Lin SH, Pytynia KB, Ferrarotto R, El-Naggar AK. Reciprocal and autonomous glucocorticoid and androgen receptor activation in salivary duct carcinoma. Clin Cancer Res. 2020;26:1175\u201384. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1603.","journal-title":"Clin Cancer Res"},{"key":"1046_CR31","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.1158\/1078-0432.CCR-12-0019","volume":"18","author":"CJ Heuck","year":"2012","unstructured":"Heuck CJ, Szymonifka J, Hansen E, Shaughnessy JD Jr., Usmani SZ, van Rhee F, et al. Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1. Clin Cancer Res. 2012;18:5499\u2013506. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0019.","journal-title":"Clin Cancer Res"},{"key":"1046_CR32","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1182\/blood.V82.8.2304.2304","volume":"82","author":"GJ Kato","year":"1993","unstructured":"Kato GJ, Quddus FF, Shuster JJ, Boyett J, Pullen JD, Borowitz MJ, et al. High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood. 1993;82:2304\u20139.","journal-title":"Blood"},{"key":"1046_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1634\/theoncologist.2014-0392","volume":"20","author":"JC Ip","year":"2015","unstructured":"Ip JC, Pang TC, Glover AR, Soon P, Zhao JT, Clarke S, et al. Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers. Oncologist. 2015;20:247\u201356. https:\/\/doi.org\/10.1634\/theoncologist.2014-0392.","journal-title":"Oncologist"},{"key":"1046_CR34","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1002\/cncr.26061","volume":"117","author":"T Mimae","year":"2011","unstructured":"Mimae T, Tsuta K, Takahashi F, Yoshida A, Kondo T, Murakami Y, et al. Steroid receptor expression in thymomas and thymic carcinomas. Cancer. 2011;117:4396\u2013405. https:\/\/doi.org\/10.1002\/cncr.26061.","journal-title":"Cancer"},{"key":"1046_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1309\/AJCPU8UCEZYG4WTV","volume":"142","author":"H Ishiguro","year":"2014","unstructured":"Ishiguro H, Kawahara T, Zheng Y, Netto GJ, Miyamoto H. Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression. Am J Clin Pathol. 2014;142:157\u201364. https:\/\/doi.org\/10.1309\/AJCPU8UCEZYG4WTV.","journal-title":"Am J Clin Pathol"},{"key":"1046_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.lungcan.2006.05.005","volume":"53","author":"YS Lu","year":"2006","unstructured":"Lu YS, Lien HC, Yeh PY, Kuo SH, Chang WC, Kuo ML, et al. Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer. 2006;53:303\u201310. https:\/\/doi.org\/10.1016\/j.lungcan.2006.05.005.","journal-title":"Lung Cancer"},{"key":"1046_CR37","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155:1309\u201322. https:\/\/doi.org\/10.1016\/j.cell.2013.11.012.","journal-title":"Cell"},{"key":"1046_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78798-x","volume":"10","author":"R Smith","year":"2020","unstructured":"Smith R, Liu M, Liby T, Bayani N, Bucher E, Chiotti K, et al. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. Sci Rep. 2020;10:21750. https:\/\/doi.org\/10.1038\/s41598-020-78798-x.","journal-title":"Sci Rep"},{"key":"1046_CR39","doi-asserted-by":"publisher","unstructured":"Hiltunen J, Helminen L, Aaltonen N, Launonen KM, Laakso H, Malinen M, et al. Androgen receptor-mediated assisted loading of the glucocorticoid receptor modulates transcriptional responses in prostate cancer cells. Genome Res. 2025. https:\/\/doi.org\/10.1101\/gr.280224.124.","DOI":"10.1101\/gr.280224.124"},{"key":"1046_CR40","doi-asserted-by":"publisher","first-page":"1437179","DOI":"10.3389\/fendo.2024.1437179","volume":"15","author":"J Hiltunen","year":"2024","unstructured":"Hiltunen J, Helminen L, Paakinaho V. Glucocorticoid receptor action in prostate cancer: the role of transcription factor crosstalk. Front Endocrinol. 2024;15:1437179. https:\/\/doi.org\/10.3389\/fendo.2024.1437179.","journal-title":"Front Endocrinol"},{"key":"1046_CR41","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/ijc.31818","volume":"144","author":"G Lakshmana","year":"2019","unstructured":"Lakshmana G, Baniahmad A. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer. Int J Cancer. 2019;144:1775\u20139. https:\/\/doi.org\/10.1002\/ijc.31818.","journal-title":"Int J Cancer"},{"key":"1046_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-023-00485-z","volume":"12","author":"V Virtanen","year":"2023","unstructured":"Virtanen V, Paunu K, Kukkula A, Niva S, Junila Y, Toriseva M, et al. Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer. Oncogenesis. 2023;12:42. https:\/\/doi.org\/10.1038\/s41389-023-00485-z.","journal-title":"Oncogenesis"},{"key":"1046_CR43","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41586-019-1019-4","volume":"567","author":"MMS Obradovic","year":"2019","unstructured":"Obradovic MMS, Hamelin B, Manevski N, Couto JP, Sethi A, Coissieux MM, et al. Glucocorticoids promote breast cancer metastasis. Nature. 2019;567:540\u20134. https:\/\/doi.org\/10.1038\/s41586-019-1019-4.","journal-title":"Nature"},{"key":"1046_CR44","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/jmcb\/mjz001","volume":"11","author":"W Shi","year":"2019","unstructured":"Shi W, Wang D, Yuan X, Liu Y, Guo X, Li J, et al. Glucocorticoid receptor-IRS-1 axis controls EMT and the metastasis of breast cancers. J Mol Cell Biol. 2019;11:1042\u201355. https:\/\/doi.org\/10.1093\/jmcb\/mjz001.","journal-title":"J Mol Cell Biol"},{"key":"1046_CR45","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.1117679","volume":"310","author":"SA Tomlins","year":"2005","unstructured":"Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644\u20138. https:\/\/doi.org\/10.1126\/science.1117679.","journal-title":"Science"},{"key":"1046_CR46","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1126\/science.1178124","volume":"326","author":"RS Mani","year":"2009","unstructured":"Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science. 2009;326:1230. https:\/\/doi.org\/10.1126\/science.1178124.","journal-title":"Science"},{"key":"1046_CR47","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1158\/1055-9965.EPI-12-0042","volume":"21","author":"A Pettersson","year":"2012","unstructured":"Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomark Prev. 2012;21:1497\u2013509. https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-0042.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1046_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-507","volume":"11","author":"JC Brase","year":"2011","unstructured":"Brase JC, Johannes M, Mannsperger H, Falth M, Metzger J, Kacprzyk LA, et al. TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer. 2011;11:507. https:\/\/doi.org\/10.1186\/1471-2407-11-507.","journal-title":"BMC Cancer"},{"key":"1046_CR49","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/modpathol.2014.70","volume":"27","author":"A Krohn","year":"2014","unstructured":"Krohn A, Freudenthaler F, Harasimowicz S, Kluth M, Fuchs S, Burkhardt L, et al. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Mod Pathol. 2014;27:1612\u201320. https:\/\/doi.org\/10.1038\/modpathol.2014.70.","journal-title":"Mod Pathol"},{"key":"1046_CR50","doi-asserted-by":"publisher","first-page":"27966","DOI":"10.18632\/oncotarget.4626","volume":"6","author":"M Kluth","year":"2015","unstructured":"Kluth M, Ahrary R, Hube-Magg C, Ahmed M, Volta H, Schwemin C, et al. Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. Oncotarget. 2015;6:27966\u201379. https:\/\/doi.org\/10.18632\/oncotarget.4626.","journal-title":"Oncotarget"},{"key":"1046_CR51","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/gcc.22645","volume":"57","author":"M Kluth","year":"2018","unstructured":"Kluth M, Scherzai S, Buschek F, Fraune C, Moller K, Hoflmayer D, et al. 13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. Genes Chromosomes Cancer. 2018;57:504\u201312. https:\/\/doi.org\/10.1002\/gcc.22645.","journal-title":"Genes Chromosomes Cancer"},{"key":"1046_CR52","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/modpathol.2012.236","volume":"26","author":"M Kluth","year":"2013","unstructured":"Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol. 2013;26:975\u201383. https:\/\/doi.org\/10.1038\/modpathol.2012.236.","journal-title":"Mod Pathol"},{"key":"1046_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcdb.2017.05.023","volume":"80","author":"JN Moloney","year":"2018","unstructured":"Moloney JN, Cotter TG. ROS signalling in the biology of cancer. Semin Cell Dev Biol. 2018;80:50\u201364. https:\/\/doi.org\/10.1016\/j.semcdb.2017.05.023.","journal-title":"Semin Cell Dev Biol"},{"key":"1046_CR54","doi-asserted-by":"publisher","unstructured":"Kokkinopoulou I, Moutsatsou P. Mitochondrial glucocorticoid receptors and their actions. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22116054.","DOI":"10.3390\/ijms22116054"},{"key":"1046_CR55","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.bbamcr.2011.05.014","volume":"1813","author":"AM Psarra","year":"2011","unstructured":"Psarra AM, Sekeris CE. Glucocorticoids induce mitochondrial gene transcription in HepG2 cells: role of the mitochondrial glucocorticoid receptor. Biochim Biophys Acta. 2011;1813:1814\u201321. https:\/\/doi.org\/10.1016\/j.bbamcr.2011.05.014.","journal-title":"Biochim Biophys Acta"},{"key":"1046_CR56","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1515\/jbcpp.2007.18.2.115","volume":"18","author":"G Bjelakovic","year":"2007","unstructured":"Bjelakovic G, Beninati S, Pavlovic D, Kocic G, Jevtovic T, Kamenov B, et al. Glucocorticoids and oxidative stress. J Basic Clin Physiol Pharm. 2007;18:115\u201327. https:\/\/doi.org\/10.1515\/jbcpp.2007.18.2.115.","journal-title":"J Basic Clin Physiol Pharm"},{"key":"1046_CR57","doi-asserted-by":"publisher","first-page":"1191311","DOI":"10.3389\/fendo.2023.1191311","volume":"14","author":"J Imamura","year":"2023","unstructured":"Imamura J, Ganguly S, Muskara A, Liao RS, Nguyen JK, Weight C, et al. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution. Front Endocrinol. 2023;14:1191311. https:\/\/doi.org\/10.3389\/fendo.2023.1191311.","journal-title":"Front Endocrinol"},{"key":"1046_CR58","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.molcel.2020.09.027","volume":"80","author":"HYK Yip","year":"2020","unstructured":"Yip HYK, Chee A, Ang CS, Shin SY, Ooms LM, Mohammadi Z, et al. Control of glucocorticoid receptor levels by PTEN establishes a failsafe mechanism for tumor suppression. Mol Cell. 2020;80:279\u201395.e8. https:\/\/doi.org\/10.1016\/j.molcel.2020.09.027.","journal-title":"Mol Cell"},{"key":"1046_CR59","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1158\/1078-0432.CCR-21-4049","volume":"28","author":"AV Serritella","year":"2022","unstructured":"Serritella AV, Shevrin D, Heath EI, Wade JL, Martinez E, Anderson A, et al. Phase I\/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2022;28:1549\u201359. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4049.","journal-title":"Clin Cancer Res"},{"key":"1046_CR60","doi-asserted-by":"publisher","first-page":"6s","DOI":"10.1200\/JCO.2023.41.6_suppl.145","volume":"41","author":"MJ Morris","year":"2023","unstructured":"Morris MJ, Linch MD, Crabb SJ, Beer TM, Heath EI, Gordon MS, et al. Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41:6s.","journal-title":"J Clin Oncol"},{"key":"1046_CR61","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.eururo.2015.10.029","volume":"69","author":"G Sauter","year":"2016","unstructured":"Sauter G, Steurer S, Clauditz TS, Krech T, Wittmer C, Lutz F, et al. Clinical utility of quantitative gleason grading in prostate biopsies and prostatectomy specimens. Eur Urol. 2016;69:592\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2015.10.029.","journal-title":"Eur Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01046-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01046-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01046-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:06:18Z","timestamp":1771272378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01046-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01046-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"29 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The GR antibody, clone HMV304 was provided from ardoci GmbH, Hamburg, Germany (owned by a family member of GS).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The use of archived remnants of diagnostic tissues for manufacturing of TMAs and their analysis for research purposes as well as patient data analysis has been approved by local laws (HmbKHG, \u00a712) and by the local ethics committee (Ethics commission Hamburg, WF-049\/09). All work has been carried out in compliance with the Helsinki Declaration. Patient consent was waived due to local laws (HmbKHG, \u00a712,1) that permit research with anonymized diagnostic left-over tissue samples.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}